Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MabpharmHKSE:02181 40 Market Cap is HK$1,794.0 Mil as of Jul. 20, 2026. GuruFocus rates HKSE:02181 with a GF Score™ of 40/100 and a GF Value™ of HK$1.97 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,423 Biotechnology companies, Mabpharm ranks better than 60.44% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Mabpharm's share price for the quarter that ended in Dec. 2025 was HK$0.5. Mabpharm's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 4,124.1 Mil. Therefore, Mabpharm's market cap for the quarter that ended in Dec. 2025 was HK$2,062.0 Mil.
Mabpharm's quarterly market cap
increased
from Dec. 2024 (HK$1,154.7 Mil) to Jun. 2025 (HK$2,000.2 Mil) and
increased
from Jun. 2025 (HK$2,000.2 Mil) to Dec. 2025 (HK$2,062.0 Mil).
Mabpharm's annual market cap
declined
from Dec. 2023 (HK$1,897.1 Mil) to Dec. 2024 (HK$1,154.7 Mil) but then
increased
from Dec. 2024 (HK$1,154.7 Mil) to Dec. 2025 (HK$2,062.0 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Mabpharm's Enterprise Value for Today is HK$2,044.8 Mil.
Mabpharm (HKSE:02181) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Mabpharm Market Cap Related Terms
Mabpharm Market Cap Historical Data
* Premium members only.
The historical data trend for Mabpharm's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02181 vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Mabpharm's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mabpharm Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mabpharm's Market Cap distribution charts can be found below:
* The bar in red indicates where Mabpharm's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Mabpharm's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mabpharm (HKSE:02181) has a Market Cap of HK$1,794.0 Mil as of Jul. 20, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Mabpharm and its competitors. According to the industry distribution chart, Mabpharm ranks #563 out of 1423 companies in the Biotechnology industry, placing it in the top 39.6%.
Is Mabpharm's Market Cap too high?
Mabpharm's current Market Cap is HK$1,794.0 Mil. Based on the distribution chart, Mabpharm ranks #563 out of 1423 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Mabpharm has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mabpharm's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Mabpharm ranks #563 out of 1423 companies for Market Cap. This puts Mabpharm in the upper half of its industry. The industry median Market Cap is 113.11. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.11, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Mabpharm and its competitors. For the Biotechnology industry, the median Market Cap is 113.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mabpharm's current Market Cap is HK$1,794.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mabpharm stock overvalued right now?
Based on GuruFocus' analysis, Mabpharm (HKSE:02181) is currently considered Possible Value Trap. The stock's GF Value™ is HK$1.97, compared to a current price of HK$0.41 — trading 79.4% below its estimated fair value. The current Market Cap is HK$1,794.0 Mil. Mabpharm's overall GF Score™ is 40/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Mabpharm (HKSE:02181), the current Market Cap is HK$1,794.0 Mil as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mabpharm (HKSE:02181) Overvalued in 2026?
Based on GuruFocus' analysis, Mabpharm stock appears to be undervalued.
The current stock price of HK$0.41 is trading 79.4% below its estimated GF Value™ of HK$1.97.
GuruFocus considers Mabpharm to be Possible Value Trap.
Key valuation signals for HKSE:02181:
Market Cap: HK$1,794.0 Mil
GF Value™: HK$1.97 vs. price of HK$0.41 (79.4% below fair value)
No single metric tells the full story. See the HKSE:02181 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mabpharm Ltd is a biopharmaceutical company. The company is engaged in the research, development, and production of new drugs and biosimilars for cancers and autoimmune diseases. Its core products include CMAB008 (infliximab), CMAB007 (omalizumab), and CMAB009 (cetuximab). Company operates in Chinese Mainland and Others.
40GF Score
Get the complete analysis for HKSE:02181
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02181 has been successfully added to your 
